 |
|
|
| |
Emergence of resistance in HIV-1 Integrase following dolutegravir (DTG)
treatment in 6 to <18 year old participants enrolled in the P1093 study
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference, 23‒25 July 2018, Amsterdam, Netherlands
Cindy Vavro1, Ted Ruel2, Andrew Wiznia3, Carmelita Alvero4, Stephanie Popson5, Terry Fenton4, Rohan Hazra6, Ellen Townley7, Ann Buchanan1, and Paul Palumbo8
Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), and by NICHDcontract number HHSN275201800001I.The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
|
| |
|
|
|
|
|
